Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Medicine in Advanced Cancer (IMPRESS-Norway)
NCT04817956Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Apr 2021
- Primary completion
- Mar 2040
- Modality
- Irreversible Covalent Inhibitors, Targeted Protein Degraders (TPDs), Antibody Conjugates
- Countries
- 1
01
Overview
Phase 2 trial of atezolizumab, bevacizumab, trastuzumab, pertuzumab, alectinib and 18 more, sponsored by Oslo University Hospital. Started Apr 2021; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT04817956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817956.